Drug Discovery@nature.com 4 April 2014

If you are unable to see the message below, click here to view.

TABLE OF CONTENTS 4 April 2014 News Analysis Research Highlights Research & Reviews Careers Nature Reviews Drug Discovery is on Twitter News Top Drug makers and NIH team up to find and validate targets doi:10.1038/nrd4293 The $230 million Accelerating Medicines Partnership stakes out new target ground in Alzheimer's disease, type 2 diabetes, rheumatoid arthritis and lupus. Full Text Schizophrenia drug gets negative results for negative symptoms doi:10.1038/nrd4294 Roche's bitopertin failed to improve the negative symptoms of schizophrenia in two pivotal trials, raising questions about the therapeutic potential of glycinergic neuromodulation. Full Text Trial watch: Bone-building antibody outshines current treatments in osteoporosis trial doi:10.1038/nrd4282 Romosozumab showed bone-building activity, which is lacking from many current therapies, in a recent Phase II trial for osteoporosis. Full Text Market watch: Upcoming market catalysts in Q2 2014 doi:10.1038/nrd4283 Important market drivers in the second quarter of 2014 include FDA approval decisions for the anticancer drug ramucirumab and the antibiotic tedizolid phosphate. Full Text Analysis Top A bitter taste for sinus infections doi:10.1038/scibx.2014.331 A new study has shown that bitter taste agonists stimulate the release of antimicrobial peptides in the sinuses, suggesting a new way to treat chronic rhinosinusitis. Full Text The COPD pipeline doi:10.1038/nrd4254 Therapeutic approaches to treat chronic obstructive pulmonary disease (COPD) are varied, and recent approvals have diversified treatment options. Full Text Research Highlights Top Antibacterial drugs: Redesigned antibiotic combats drug-resistant tuberculosis doi:10.1038/nrd4287 A novel class of anti-TB agents, called spectinamides, has shown activity against multidrug-resistant TB. Full Text Cancer: Live screening of immunotherapy targets doi:10.1038/nrd4289 A new study has outlined an approach for the in vivo discovery of immunotherapy targets in melanoma using RNA interference technology. Full Text Neurodegenerative disease: Searching for the weak spots doi:10.1038/nrd4284 Matrix metalloproteinase 9 could be a promising therapeutic target for amyotrophic lateral sclerosis. Full Text Research & Reviews Top Aquaporins: important but elusive drug targets doi:10.1038/nrd4226 The authors discuss the therapeutic potential of targeting aquaporin channels as well as associated challenges, such as the suitability of assay methods. Full Text Targeting the pancreatic β-cell to treat diabetes doi:10.1038/nrd4231 Wagner and colleagues discuss strategies to promote β-cell proliferation, survival and function for the treatment of diabetes, and consider ongoing challenges to drug development efforts that are aimed at targeting this cell population. Full Text Advances in targeting cyclic nucleotide phosphodiesterases doi:10.1038/nrd4228 A review of how recent understanding of the roles of individual cyclic nucleotide phosphodiesterases (PDEs) is aiding the development of more sophisticated strategies to target individual PDE variants. Full Text Pathological pain and the neuroimmune interface doi:10.1038/nri3621 The authors explain how the immune and nervous systems interact to initiate and propagate pain, and discuss the immune components that can be targeted for alleviating pathological pain in patients. Full Text Drug Discovery JOBS of the week Postdoc in Cancer Drug Delivery University of Tartu PhD Position on Bionanotechnology for Sensing, Drug Delivery and Cell Culture Universitat Rovira i Virgili-DEEEA 4-Year Fully Funded Studentship in "Computation of Allosteric Interactions in Biomolecular Drug Targets’’ University of Edinburgh Scientific Officer - Molecular Drug Resistance Team Institute of Cancer Research (ICR) Tenure-Track and Postdoctoral Scientists in Molecular Profiling Research Center for Drug Discovery, AIST National Institute Advanced Industrial Science and Technology (AIST) More Science jobs from Drug Discovery EVENT 15th International Conference on Alzheimer’s Drug Discovery 08.09.14 New Jersey, USA More science events from Careers Top Career snapshots archive Career snapshots feature people associated with drug discovery and drug development, with the aim of providing expert insights and advice on a wide range of positions and career paths in this field. Full Text Top Natureevents is a fully searchable, multi-disciplinary database designed to maximise exposure for events organisers. The contents of the Natureevents Directory are now live. The digital version is available here. Find the latest scientific conferences, courses, meetings and symposia on natureevents.com. For event advertising opportunities across the Nature Publishing Group portfolio please contact natureevents@nature.com More Nature Events

You have been sent this Table of Contents Alert because you have opted in to receive it. You can change or discontinue your e-mail alerts at any time, by modifying your preferences on your nature.com account at: www.nature.com/myaccount (You will need to log in to be recognised as a nature.com registrant) For further technical assistance, please contact our registration department For print subscription enquiries, please contact our subscription department For other enquiries, please contact our customer feedback department Nature Publishing Group | 75 Varick Street, 9th Floor | New York | NY 10013-1917 | USA Nature Publishing Group's worldwide offices: London - Paris - Munich - New Delhi - Tokyo - Melbourne San Diego - San Francisco - Washington - New York - Boston Macmillan Publishers Limited is a company incorporated in England and Wales under company number 785998 and whose registered office is located at Brunel Road, Houndmills, Basingstoke, Hampshire RG21 6XS. © Nature Publishing Group, a division of Macmillan Publishers Limited. All Rights Reserved.